SCNI revenueFY2025$1.31M
- FY YoY
- +99.2%
SCNI revenue was $1.31M for fiscal 2025 (ended Dec 31, 2025), up 99.2% from fiscal 2024.
Scinai Immunotherapeutics Ltd. (SCNI) financials
For fiscal 2025 (ended Dec 31, 2025), Scinai Immunotherapeutics Ltd. reported $1.31M of revenue and -$8.31M of net income.
- Revenue, FY2025
- $1.31M
- Revenue growth, YoY
- +99.2%
- Net income, FY2025
- -$8.31M
- Net margin
- -633.6%
- Free cash flow, FY2025
- -$6.05M
- Cash
- $1.66M
- P/S
- 0.88
- Market cap
- $1.2M
FY2024FY2025
FY2017FY2025
FY2017FY2025
SCNI revenue and earnings growth
SCNI net incomeFY2025-$8.31M
SCNI net income was -$8.31M for fiscal 2025 (ended Dec 31, 2025), compared with $4.80M in fiscal 2024.
SCNI free cash flowFY2025-$6.05M
SCNI free cash flow was -$6.05M for fiscal 2025 (ended Dec 31, 2025), compared with -$6.35M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | $1.31M | $658.0K | - | - | - | - | - |
| Cost of revenue | $3.96M | $1.24M | - | - | - | - | - |
| Gross profit | -$2.65M | -$580.0K | - | - | - | - | - |
| Research and development | $2.37M | $5.53M | $5.21M | $5.76M | $3.25M | $16.01M | $5.42M |
| Selling, general and admin | $2.52M | $2.53M | $4.50M | $5.30M | $7.63M | $5.19M | $1.41M |
| Operating income | -$7.54M | -$8.64M | -$9.71M | -$11.06M | -$10.86M | - | - |
| Interest expense | - | - | $343.0K | $351.0K | $336.0K | $4.86M | $3.15M |
| Net income | -$8.31M | $4.80M | -$6.50M | -$5.80M | -$8.21M | -$1.39M | -$9.97M |
| EPS, basic | - | - | $0.00 | $0.01 | -$0.02 | - | - |
| EPS, diluted | - | - | $0.00 | $0.01 | -$0.02 | - | - |
| Diluted shares | 9.34B | 3.23B | 1.56B | 754.1M | 564.6M | 443.3M | 201.0M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2017 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $1.66M | $1.96M | $4.87M | $14.21M | $17.52M | $3.08M | $20.59M |
| Receivables | $73.0K | $83.0K | - | - | $325.0K | $375.0K | $1.13M |
| Current assets | $2.05M | $2.39M | $5.45M | $14.37M | $17.84M | $3.31M | $21.72M |
| Total assets | $11.63M | $13.45M | $17.47M | $27.07M | $32.04M | $17.70M | $23.56M |
| Current liabilities | $1.58M | $1.81M | $1.78M | $2.34M | $2.44M | $19.96M | $1.99M |
| Short-term debt | - | - | - | $382.0K | $375.0K | - | - |
| Total liabilities | - | - | - | $28.83M | $31.05M | $22.24M | $7.34M |
| Shareholders' equity | $8.10M | $9.98M | -$4.57M | -$1.76M | $982.0K | -$15.04M | $16.23M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2017 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$6.03M | -$6.33M | -$9.38M | -$7.26M | -$7.43M | -$22.56M | -$2.90M |
| Capital expenditures | $24.0K | $12.0K | $637.0K | $836.0K | $139.0K | $1.91M | $1.30M |
| Free cash flow | -$6.05M | -$6.35M | -$10.02M | -$8.10M | -$7.57M | -$24.47M | -$4.20M |
| Investing cash flow | -$24.0K | -$12.0K | -$637.0K | -$836.0K | -$139.0K | -$1.84M | $1.95M |
| Financing cash flow | $5.77M | $3.44M | $1.09M | $6.78M | $21.43M | $4.27M | $17.84M |
| Stock-based compensation | $303.0K | $682.0K | $1.14M | $1.60M | $2.76M | $2.95M | $150.0K |
| Depreciation and amortization | $1.42M | $1.65M | $514.0K | $562.0K | $471.0K | - | - |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2017 |
|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | 99.2% | - | - | - | - | - | - |
| Gross margin | -202.3% | -88.1% | - | - | - | - | - |
| Operating margin | -575.3% | -1312.8% | - | - | - | - | - |
| Net margin | -633.6% | 728.9% | - | - | - | - | - |
| Free cash flow margin | -461.9% | -964.6% | - | - | - | - | - |
| Return on equity | -102.5% | 48.1% | - | - | -835.6% | - | -61.4% |
| Return on assets | -71.5% | 35.7% | -37.2% | -21.4% | -25.6% | -7.8% | -42.3% |
| Current ratio | 1.30 | 1.32 | 3.06 | 6.15 | 7.30 | 0.17 | 10.94 |
Income statement
| Line item | Mar 31, 2023 | Mar 31, 2022 |
|---|---|---|
| Research and development | $2.00M | $1.16M |
| Selling, general and admin | $1.19M | $1.45M |
| Operating income | -$3.19M | -$2.62M |
| Net income | -$3.52M | -$2.48M |
| EPS, basic | -$0.00 | -$0.00 |
| EPS, diluted | -$0.00 | -$0.00 |
| Diluted shares | 1.30B | 744.7M |
Balance sheet
| Line item | Mar 31, 2023 | Mar 31, 2022 |
|---|---|---|
| Cash and equivalents | $10.80M | $15.39M |
| Current assets | $11.04M | - |
| Total assets | $23.29M | - |
| Current liabilities | $2.58M | - |
| Shareholders' equity | -$4.81M | -$862.0K |
Cash flow
| Line item | Mar 31, 2023 | Mar 31, 2022 |
|---|---|---|
| Operating cash flow | -$3.06M | -$1.10M |
| Capital expenditures | $6.0K | $521.0K |
| Free cash flow | -$3.06M | -$1.63M |
| Investing cash flow | -$6.0K | -$521.0K |
| Stock-based compensation | $252.0K | $485.0K |
| Depreciation and amortization | $138.0K | $134.0K |
Key ratios
Source: XBRL data Scinai Immunotherapeutics Ltd. files with the SEC, latest filing dated Apr 1, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
SCNI peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| SCNI | $1.31M | +99.2% | -$8.31M | -633.6% | $1.2M |
| AMGN | $38.90B | +8.2% | $9.39B | 24.1% | $249.05B |
| GILD | $30.99B | +6.5% | -$3.86B | -12.5% | $207.00B |
| MRNA | $2.52B | +13.1% | -$2.79B | -110.5% | $101.48B |
| ARGX | $4.25B | +88.6% | $1.29B | 30.4% | $57.55B |
| RVMD | $0 | - | -$1.13B | - | $41.59B |
| BIIB | $10.30B | +2.3% | $347.50M | 3.4% | $36.71B |
| BNTX | €2.87B | +4.3% | -€1.14B | -39.6% | $21.98B |
| EXEL | $2.50B | +9.1% | $885.14M | 35.5% | $16.98B |
SCNI FAQ
8 questionsWhat is SCNI revenue?
Scinai Immunotherapeutics Ltd. (SCNI) reported $1.31M of revenue for fiscal 2025 (ended Dec 31, 2025). That is up 99.2% from the year before.Is SCNI profitable?
No. Scinai Immunotherapeutics Ltd. reported a net loss of $8.31M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does SCNI have?
Scinai Immunotherapeutics Ltd. reported $1.66M in cash and cash equivalents on its most recent balance sheet in SEC filings.How fast is SCNI revenue growing?
Scinai Immunotherapeutics Ltd.'s revenue changed +99.2% in fiscal 2025, to $1.31M.What is SCNI gross margin?
Scinai Immunotherapeutics Ltd.'s gross profit was -$2.65M on $1.31M of revenue for fiscal 2025 (ended Dec 31, 2025), a gross margin of -202.3%.What is SCNI free cash flow?
Scinai Immunotherapeutics Ltd. generated -$6.05M of free cash flow for fiscal 2025 (ended Dec 31, 2025), which is operating cash flow of -$6.03M less capital expenditures.When did SCNI last report financial results?
The latest statements here come from Scinai Immunotherapeutics Ltd.'s 20-F filed on Apr 1, 2026, covering the period ended Dec 31, 2025.Where does this SCNI financial data come from?
Quantisnow builds these statements from the structured XBRL data Scinai Immunotherapeutics Ltd. files with the SEC. It is provided for information only and is not investment advice.